Ocular Therapeutix Inc (OCUL) FinancialsOCULFinancialOcular Therapeutix Inc

Evaluating the bottom line, Ocular Therapeutix, Inc. maintains a gross margin of 85.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -609.34%, while the net margin is -584.51%. These profitability ratios, combined with a Return on Equity (ROE) of -72.99%, provide a clear picture of how effectively OCUL converts its operational activities into shareholder value.

In the context of the broader market, OCUL competes directly with industry leaders such as HRMY and BHVN. With a market capitalization of $2.20B, it holds a significant position in the sector. When comparing efficiency, OCUL's gross margin of 85.08% stands against HRMY's 75.81% and BHVN's N/A. Such benchmarking helps identify whether Ocular Therapeutix, Inc. is trading at a premium or discount relative to its financial performance.

Ocular Therapeutix has shown strong gross margins, with figures around 85% to 92% in recent quarters, indicating effective cost management despite ongoing losses. However, the company has consistently reported negative net income, with Q2 2026 showing a loss of -78.76 million, reflecting ongoing financial challenges.